Introduction
The male blue fox (Alopex lagopus) is a seasonal breeder, with 5-fold annual changes in testicular size and associated seasonal changes in blood concentrations of a range of hormones (Smith et al, , 1986 . These variations are probably influenced by seasonal changes in environmental cues such as daylength and temperature, but little is known about the neuroendocrine mechanisms that mediate these cues. Males of other species exhibit variations in plasma concentrations of pro¬ lactin that appear to be well correlated to photoperiod, with highest values during long days, both in the Northern hemisphere (e.g. ram: Ravault, 1976 ; goat: Buttle, 1974 ; white-tailed deer : Mirarchi et al, 1978) and Southern hemisphere (e.g. ram: Kennaway et al, 1981) . The development of a specific radioimmunoassay for prolactin in the blue fox revealed a similar correlation in this species .
The role of prolactin in the control of male reproductive function is still poorly understood (Bartke, 1980) . The effects of prolactin undoubtedly vary depending on the species concerned, the age of the animal and, under experimental conditions, dosage and time of administration. In the golden hamster at least, alterations in prolactin release provide one of the mechanisms that mediate the effect of photoperiod on the testis (for review see Bartke et al, 1985) .
Control of the moulting cycle, on the other hand, and the roles of prolactin and melatonin secretion in the mediation of photoperiodic cues, are more fully understood. We have previously shown that melatonin administration depresses plasma prolactin concentrations in the male blue fox and delays the spring moult (Smith et al, 1987a) . A similar situation exists in mink ; in addition, prolactin injections induce an early spring moult . Likewise, experimental work in mink suggests that a decline in plasma prolactin concentrations, whether produced by administration of melatonin , maintenance of the animals under short days (Rose et al, 1985) , or bromocriptine treatment (Martinet et al, 1984; Rose et al, 1987) plays a central role in the control of the autumn moult. It is likely that melatonin influences the release of LHRH, dopamine and other factors from the hypothalamus which in turn regulate the secretion of LH, FSH and prolactin from the anterior pituitary (Cardinali, 1981) , thereby influencing gonadal activity and fur growth.
Bromocriptine inhibits prolactin release, both by binding to dopamine receptors on anterior pituitary cells (Coronin et al, 1978) and by decreasing dopamine turnover (Fuxe et al, 1978) . Bromocriptine has previously been shown to depress plasma prolactin concentrations in, among other species, the male blue fox , male golden hamster (Stroud et al, 1985) and ram .
The purpose of the present study was to test, by using bromocriptine, the suspected involvement of prolactin in mediating the effects of melatonin on testicular regression and the spring moult by depressing the physiological rise in plasma prolactin as daylength increases. One of the foxes in the group receiving bromocriptine had to be killed on 14 June because of an injury unrelated to the study.
Blood collection. Blood samples (10 ml) were collected 1-3 times weekly into heparinized tubes without anaesthesia between 09:00 and 11:00 h, using light manual restraint. Plasma was separated by centrifugation and stored at -20°C until assay.
Hormone assays. Blood samples were analysed for prolactin and testosterone using specific radioimmunoassays previously described and validated for use in the blue fox (prolactin: testosterone: Moller et a!, 1984). For the prolactin assay, the sensitivity was 2 ng/ml and the intra-and inter-assay coefficients of variation were 8-1 % and 13-9% respectively. The corresponding values for the testosterone assay were 20 pg/ml, 4-9% and 11-7%, respectively. Plasma concentrations of FSH were measured by a heterologous radioimmunoassay (unpublished). This assay utilized an anti-human FSH antiserum (M91/1) donated by A. S. McNeilly, a purified canine FSH preparation (LER-1685-3A) as reference standard and a highly purified ovine FSH (LER-1976-A2) for iodination as tracer, provided by L. E. Reichert. The mean detection limit was 20 ng/ml and the intra-and inter-assay coefficients of variation were 60% and 10-6%, respectively.
All serial samples from the same animal were measured in duplicate in one assay. Measurement of testicular volume. The length (which included the head of the epididymis) and width of the testes of all males were measured through the scrotum by using calipers, with no allowance for scrotal skin thickness, at approximately 10-day intervals during the study period. Values for length (2a) and width (2b) were converted to volumes (V) by means of the formula for a prolate spheroid, V = l-33nab2 (Wildt et a!, 1982) .
DNA flow cytometry. On 3 July 1985 testicular biopsies were taken from 6 of the 7 males still alive, as described previously (Smith et a!, 1987a (4) spermatogonia, spermatocytes and elongated spermatids, with or without round spermatids. The normal seasonal variations in the occurrence of these categories in both immature and adult males have been described elsewhere (Smith et al, 1986 (Smith et al, , 1987b .
Examination offur. The males were killed on 14-15 August 1985 and the skins sent to Oslo Fur Auctions where they were assessed for pigmentation, maturation of the fur, hair quality, coat density and texture.
Results

Plasma prolactin
As shown in Fig. 1 (a) a normal rise in prolactin concentrations occurred in the controls, from 2-7-9-7 ng/ml in March (mean 4-9 ng/ml, = 12) to 7-3-20-7 ng/ml in May and June (mean 12-4 ng/ml, = 28). This rise was totally abolished in the treatment group, in which plasma prolactin concentrations remained low throughout the study period (2-1-60 ng/ml).
Plasma FSH Plasma FSH concentrations (Fig. lb) remained low throughout the study period in the control and treatment group (controls: non-detectable-100 ng/ml; treated: non-detectable-44 ng/ml).
Plasma testosterone
Plasma concentrations of testosterone fell gradually in a similar way in the control and treated animals ( Fig. lc) from March (controls: 0-51-9-36 ng/ml, mean 5-1 ng/ml, = 12; treated: 0-78-4-35 ng/ml, mean 21 ng/ml, = 8) to July and August (controls: 0-03-2-59 ng/ml, mean 0-4 ng/ml, = 24; treated: 002-1 06 ng/ml, mean 0-4 ng/ml, = 18).
Testicular regression
Testicular regression, as judged by testicular volume, appeared to be delayed in the treated animals compared with the controls (Fig. Id) 
Moulting cycle
The control animals underwent a normal moult during May and June. None of the treated males, however (including the fox which was killed on 14 June), lost their winter coat. The typical appearance in July 1985 of males in the control group and of those receiving bromocriptine is illustrated in Fig. 2 . All 3 of the foxes given bromocriptine had mature winter pelts, with normal hair quality, texture and density. Two of the pelts gave the impression of having undergone a change of hair pigment, especially in the guard hairs, to a uniform beige/yellow colour. The third was discoloured by urine.
Discussion
The present study shows that bromocriptine treatment initiated in March suppresses the annual rise in plasma prolactin concentrations that normally occurs during increasing daylength (MayJune) and prevents the spring moult. Previous (unpublished) studies have shown the same effect even when bromocriptine treatment was begun as late as May, after plasma prolactin concen¬ trations have started to increase; these males retained the winter coat through the following winter and moulted normally in the spring.
Bromocriptine treatment appeared also to influence testicular regression, despite the fact that testosterone concentrations remained unchanged. The mechanism of this effect is unclear: bromo¬ criptine treatment has been reported to stimulate FSH release in sheep (Ravault et al, 1982) , but no such effect was seen in the present study (Fig. lb) . High doses of bromocriptine may also interfere with other hormones, in particular LH (Shaban & Terranova, 1986) , growth hormone (Flückiger et al, 1976) and MSH (Penny et al, 1979) .
Prolactin is believed to modify the sensitivity of the hypothalamic-pituitary axis to testosterone feedback during testicular regression of the golden hamster (Matt et al, 1984) . There is, however, no evidence for this in the blue fox; suppression of the spring rise in plasma prolactin concen¬ trations by melatonin does not appear to alter LH release despite the fact that testosterone produc¬ tion is prolonged (Smith et al, 1987a) . A decrease in testosterone secretion does not appear to be the primary stimulus for the spring moult since this moult and the simultaneous rise in plasma prolactin concentrations continue normally after castration .
Other studies also indicate that there is no fixed relationship between the rise in plasma prolactin concentrations and the breeding season. Carr & Land (1982) It is still unclear whether the rise in prolactin is triggered by increasing daylength or tempera¬ ture. The effects of these 2 variables are impossible to differentiate under natural conditions since both show marked and parallel annual changes at this latitude . Plasma pro¬ lactin concentrations in golden and Djungarian hamsters, maintained in constant temperature, change readily in response to photoperiod (Bex et al, 1978; Duncan & Goldman, 1984) . Studies of other species, however, have demonstrated a rise in prolactin values in response to increasing temperature (cattle: Tucker & Wettemann, 1976; rat: Mueller et al, 1974) .
Studies of mink indicate that both the furring cycle and testicular development may also be influenced by a-MSH secretion (Ellis et al, 1982) . Work on the Djungarian hamster (Duncan & Goldman, 1984) , however, suggests that the effects of bromocriptine on the pelage colour cycle are mediated by prolactin suppression alone, without any suppression of MSH. Burchill & Thody (1986) suggest direct effects of dopaminergic agents on hair follicles. Further studies are clearly warranted before the changes seen in the present study after bromocriptine treatment can be ascribed to the reduction in plasma prolactin concentrations.
